BOSTON, Aug. 29, 2024 ~ Lexington, MA - Medicilon USA Corp (Medicilon) has officially opened its second R&D center in Massachusetts, USA in August 2024. The new facility will focus on animal models for PK/PD and toxicology studies, marking a significant milestone in the company's global business expansion.

The decision to establish the Lexington location was made with the aim of enhancing synergy and communication with industry partners. By being in close proximity to numerous top biotech companies and research institutions, Medicilon hopes to contribute even more to pharmaceutical innovation.

The Lexington site will provide critical research services while ensuring smooth communication with both industry-based and academic drug development teams. This commitment to quality and innovation will keep Medicilon's research partners competitive as new therapeutic technologies continue to emerge.

In addition, the U.S. R&D service matrix has been upgraded to empower accelerated development of novel drug modalities. The new laboratory supplements Medicilon's diverse R&D platforms with cutting-edge resources, including advanced instrumentation and animal laboratories. The site also boasts a rich animal model library, with over 410 tumor efficacy models and over 240 non-tumor target research animal models. Elite scientists at the center will perform efficacy evaluation of small molecule drugs and biologics, as well as pharmacokinetic evaluation and optimization, all in compliance with ICH, NMPA, and FDA standards.

More on Boston Chron

• How to Fast-Track Your Way to the Top with The Code
• Lyricalmar Set To Release Powerful New Ep "MARCHIVES" May 16
• Charleston, SC - ACSEC offers Rain Barrels Through Annual Program
• Greek Government Issues Landmark Ministerial Order Addressing Citizenship of Greek-born adoptees
• Boston: Bridging the Digital Divide by Embedding Digital Skills in Workforce Development

Medicilon has been steadily building an international collaborative network since it began providing preclinical filing applications that meet both Chinese GLP and U.S. GLP standards. The company first established a presence in Boston in 2016 for its U.S. business operations, and by 2023 had already commenced local research projects for key partners in the country. With the expansion of its Massachusetts R&D center, Medicilon's international service capabilities will be significantly enhanced, demonstrating its proactive response to the continual changes in drug development trends.

Dr. Qingcong Lin, President of Medicilon USA, expressed excitement about the company's presence in Boston, stating that "with its top-tier pharmaceutical innovation and technological resources, [Boston] is a strategic choice for Medicilon to enhance its presence." He also added that the company will leverage local advantages to stimulate internal potential, strengthen technological capabilities, and explore new fields in drug development through innovation and collaboration.

More on Boston Chron

• Baltimore Author Crafts Space Opera Where Human Questions Outshine Galactic Scale
• Stout Surpasses 60,000 Acres and 3 Billion Plants Scanned
• OpsVeda Announces Launch of TariffSight, the World's First Comprehensive Platform to Address Tariff-Driven Challenges
• MAJOR New release of Krypto500 (ELF-HF) Sigint - COMINT software
• New Build-to-Suit VA Medical Office Facility Coming to Highland Heights, KY

Dr. Chunlin Chen, Founder and CEO of Medicilon, also shared his thoughts on the expansion, saying that "relying on the Boston R&D center, Medicilon will more closely connect with the global pharmaceutical innovation ecosystem and continuously drive technological innovation and service upgrades." He emphasized the company's commitment to becoming a globally trusted comprehensive preclinical research service CRO in the pharmaceutical industry.

The opening of Medicilon's second R&D center in Massachusetts is a significant step towards achieving these goals. With its state-of-the-art facilities and highly skilled scientists, the company is poised to make even greater contributions to pharmaceutical innovation on a global scale.

---

Show All News | Report Violation